Back to top
more

RxSight (RXST)

(Delayed Data from NSDQ)

$7.19 USD

7.19
1,667,105

-0.60 (-7.70%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $7.20 +0.01 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

RxSight (RXST) delivered earnings and revenue surprises of +20.00% and +0.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

FMS vs. RXST: Which Stock Is the Better Value Option?

by Zacks Equity Research

FMS vs. RXST: Which Stock Is the Better Value Option?

Zacks Equity Research

FMS or RXST: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

FMS vs. RXST: Which Stock Is the Better Value Option?

Zacks Equity Research

KMDA vs. ACAD: Which Stock Is the Better Value Option?

by Zacks Equity Research

KMDA vs. ACAD: Which Stock Is the Better Value Option?

Zacks Equity Research

Do Options Traders Know Something About RxSight Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to RXST stock based on the movements in the options market lately.

Zacks Equity Research

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

RxSight (RXST) delivered earnings and revenue surprises of 25% and 0.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

RxSight, Inc. (RXST) Misses Q4 Earnings Estimates

by Zacks Equity Research

RxSight (RXST) delivered earnings and revenue surprises of -70% and 0.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RxSight (RXST) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

RxSight (RXST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3

by Zacks Equity Research

RxSight (RXST) delivered earnings and revenue surprises of -100% and 0.47%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2

by Zacks Equity Research

RxSight (RXST) delivered earnings and revenue surprises of 100% and 8.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround

by Zacks Equity Research

RxSight (RXST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for RxSight (RXST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

What Makes RxSight, Inc. (RXST) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Nalak Das headshot

Buy 5 Medical Instruments Stocks to Enhance Your Portfolio

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.

Zacks Equity Research

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYC

Zacks Equity Research

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYC

Zacks Equity Research

What's in the Offing for Brainsway (BWAY) in Q4 Earnings?

by Zacks Equity Research

Brainsway's (BWAY) fourth-quarter 2023 performance is likely to have been impacted by the strong momentum across the entire business.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zacks Equity Research

Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?

by Zacks Equity Research

Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.

Zacks Equity Research

Charles River (CRL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.

Zacks Equity Research

IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4.